Why the study?
What are the prognostic outcomes and risk factors for patients with renal cell carcinoma and venous tumor thrombus undergoing radical nephrectomy and thrombectomy?
What are the prognostic outcomes and risk factors for patients with renal cell carcinoma and venous tumor thrombus undergoing radical nephrectomy and thrombectomy?
Patients with RCC and venous tumor thrombus can achieve promising long-term survival after radical nephrectomy and thrombectomy, particularly those with early-stage thrombus.
Answers are grounded in this paper and cite their sources.
Supports risk-adapted surveillance after nephrectomy and thrombectomy; leaves open whether adjuvant therapies benefit high-risk patients.
INTRODUCTION: To evaluate the prognostic outcomes and risk factors for renal cell carcinoma (RCC) patients with venous tumor thrombus in China. MATERIALS AND METHODS: We reviewed the clinical information of 169 patients who underwent radical nephrectomy and thrombectomy. Overall and cancer-specific survival rates were analyzed. Univariate and multivariate analyses were used to investigate the potential prognostic factors. RESULTS: The median survival time was 63 months. The five-year overall survival and cancer-specific survival rate were 53.6% and 54.4% for all patients. For all patients, significant survival difference was only observed between early (below hepatic vein) and advanced (above hepatic vein) tumor thrombus. However, significant differences existed between both RV/IVC and early/advanced tumor thrombus groups in N0M0 patients. Multivariate analysis demonstrated that higher tumor thrombus level (p = 0.016, RR = 1.58), N (p = 0.013, RR = 2.60), and M (p < 0.001, RR = 4.14) stages and adrenal gland invasion (p = 0.001, RR = 4.91) were the most significant negative prognostic predictors. CONCLUSIONS: In this study, we reported most cases of RCC patients with venous extension in China. We proved that patients with RCC and venous tumor thrombus may have relative promising long-term survival rate, especially those with early tumor thrombus.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: